Sample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials

DOI10.2307/2531910MaRDI QIDQ118080zbMATH OpenOpenAlexWikidataFDO

Authors Edward Lakatos

Publication date March 1988

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.2307/2531910

zbMATH Keywords

complex clinical trialslog-rank statisticMarkov processnoncompliancenonproportional hazardssample sizestaggered entryTarone-Ware class

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• A Sample Size Formula for the Supremum Log‐Rank Statistic
• Tests for comparing estimated survival functions
• Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification
• Sample-size formula for clustered survival data using weighted log-rank statistics
• Sample size and power for the weighted log‐rank test and Kaplan‐Meier based tests with allowance for nonproportional hazards

Cited in

(40)

• Sample size calculation for the log-rank tests for multi-arm trials with a control
• nphPower
• The effect of grouping on the power of the Mantel-Haenszel test for the comparison of survival rates
• Data monitoring in complex clinical trials: Which treatment is better?
• Sample size calculation for rank tests comparing \(K\) survival distributions
• Sample size calculation for the proportional hazards model with a time-dependent covariate
• A comparison of the constant piecewise weighted logrank and Fleming-Harrington tests
• Sample size calculation for clustered survival data under subunit randomization
• Cross-product ratio calculation under different sampling schemes in clinical trials -- case study of the CYP-GUIDES trial
• Minimum size survival analysis sampling plans for comparing multiple treatment groups to a single control group
• Adaptive designs for the one-sample log-rank test
• Nonparametric Estimation of Duration of Accrual and Total Study Length for Clinical Trials
• Sample-Size Formula for the Proportional-Hazards Regression Model
• Calculation of Sample Size in Survival Trials: The Impact of Informative Noncompliance
• Sample size selection in clinical trials when population means are subject to a partial order: one-sided ordered alternatives
• Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification
• A note on variance estimation in the Cox proportional hazards model
• A simple procedure to estimate the optimal sample size in case of conjunctive coprimary endpoints
• A Sample Size Formula for the Supremum Log‐Rank Statistic
• The Influence of Biostatistics at the National Heart, Lung, and Blood Institute
• Sample size calculation for two‐arm trials with time‐to‐event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions
• Sample size calculation for the combination test under nonproportional hazards
• Designing a phase-III time-to-event clinical trial using a modified sample size formula and Poisson-Gamma model for subject accrual that accounts for the lag in site initiation using the PERT distribution
• Assurance methods for designing a clinical trial with a delayed treatment effect
• Complex survival trial design by the product integration method
• Sequential trials in the context of competing risks: concepts and case study, with R and SAS code
• Design and monitoring of survival trials in complex scenarios
• Novel application of a discrete time-to-event model for randomized oral immunotherapy clinical trials with repeat food challenges
• Sample size calculation for cluster randomization trials with a time-to-event endpoint
• A Bayesian adaptive phase III design for multi-arm trials with time-to-event endpoint for nonproportional hazards utilizing the generalized gamma distribution
• Sample size for competing risks survival analysis in fixed and group-sequential designs
• Balancing events, not patients, maximizes power of the logrank test: and other insights on unequal randomization in survival trials
• Design and analysis of clinical trials in the presence of delayed treatment effect
• Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata
• Power of the Mantel-Haenszel and other tests for discrete or grouped time-to-event data under a chained binomial model
• A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution
• Designing therapeutic cancer vaccine trials with delayed treatment effect
• A bi-endpoint expectation-maximisation algorithm for re-estimating sample size for the time-to-event endpoint under the blind condition
• Designing cancer immunotherapy trials with random treatment time-lag effect
• Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks

This page was built for publication: Sample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q118080)